Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Compugen Ltd.NASDAQ: CGEN

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income of $56.85M in Q4 FY2025

Q4 FY2025 net income was $56.85M. Trailing-twelve-month net income was $35.34M.

Context

  • Net income amounted to 48.6% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$23.7M (-167.1%) for the fiscal year ending Dec 2026, a slowdown from the +348.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
$56.85M+914.5% QoQ
Last fiscal yearDec 2025
$35.34M+348.4% YoY
LTMDec 2025
$35.34M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter—-7.6%—
1 year+348.4%-167.1%-515.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
35.34M USD
Year-over-year change
+348.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Net income amounts to 48.6% of revenue for CGEN, versus a peer median of 1764.5%.
CGEN Competitors
Net Income for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$147.39M USD+11.7%+4.0%839.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$84.53M USD+68.1%+22.9%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.36M USD+31.7%+2.6%3832.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44.76M USD-8.4%+5.8%8526.1%
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$31.7M USD-25.4%-22.3%1000.2%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$29.59M USD+46.8%+11.5%—
Peer median (excluding CGEN) —+9.8%+4.0%1764.5%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Depreciation & Amortization461K482K476K486K475K
Deferred Income Tax00000
Stock-Based Compensation4.28M4.33M3.55M3.02M0
Change in Working Capital6.82M(5.55M)(20.71M)62.05M(5.35M)
Accounts Receivables2M3.04M(61.11M)59.93M360K
Inventory(3.37M)0000
Accounts Payables3.37M(1.6M)3.51M(4.41M)517K
Other Working Capital3.79M(7M)36.9M6.53M(6.23M)
Other Non-Cash Items(573K)515K(452K)(1.72M)1.16M
Operating Cash Flow(22.75M)(34.51M)(35.89M)49.6M31.63M
Capital Expenditures(292K)(487K)(172K)(118K)(306K)
Acquisitions (Net)3K2K001K
Purchases of Investments(129.95M)(76.9M)(53.71M)(159.75M)(96.07M)
Sales of Investments136.85M114.45M89.39M113.95M126.37M
Other Investing Activities000(329K)0
Investing Cash Flow6.62M37.06M35.51M(46.25M)30M
Debt Repayment00000
Common Stock Issued14.96M353K3.08M544K10.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.88M0010K(4K)
Financing Cash Flow16.84M353K3.08M554K10.6M
Effect of Forex Changes469K(584K)129K68K135K
Net Change in Cash704K2.91M2.83M3.97M72.37M
Free Cash Flow(23.04M)(34.99M)(36.06M)49.49M31.33M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.